In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy.

Boron neutron capture therapy (BNCT) requires pharmaceutical innovations and molecular-based evidence of effectiveness to become a standard cancer therapeutic in the future. Recently, in Japan, 4-borono-L-phenylalanine (BPA) was approved as a boron agent for BNCT against head and neck (H&N) cancers. H&N cancer appears to be a suitable target for BPA-BNCT, because the expression levels of L-type amino acid transporter 1 (LAT1), one of the amino acid transporters responsible for BPA uptake, are elevated in most cases of H&N cancer.

Catalytic cycloaddition of 2-methyleneaziridines with 1,1-dicyanoalkenes.

2-Methyleneaziridine are a good substrate for the catalytic synthesis of cyclopentylidenamines via a [3 + 2] cycloaddition of 1,1-dicyanoalkenes using Bu2SnI2 as an effective catalyst. A C-attack from 2-methyleneaziridine yielded the desired products.